Forgiveness of INSTI-Containing Regimens at Drug Concentrations Simulating Variable Adherence In Vitro

Long Dissociation of Bictegravir from HIV-1 Integrase-DNA Complexes

(2021) Kirsten L. White et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy–naive adults with HIV-1 infection

(2021) Pedro Cahn et al.   AIDS

Case Report: Emergent Resistance in a Treatment-Naive Person With Human Immunodeficiency Virus Under Bictegravir-Based Therapy

(2021) Nicholas Chamberlain et al.   Open Forum Infectious Diseases

Failure to Biktarvy® and development of resistance mutations in an antiretroviral-experienced patient

(2020) Ana Belén Lozano et al.   ANTIVIRAL RESEARCH

Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose Two-Drug Regimen Versus Continuing a Tenofovir Alafenamide–Based Three- or Four-Drug Regimen for Maintenance of Virologic Suppression in Adults With HIV-1: Phase 3, Randomized, Non-inferiority TANGO Study

(2020) Jean van Wyk et al.   CLINICAL INFECTIOUS DISEASES

Structural basis of second-generation HIV integrase inhibitor action and viral resistance

(2020) Nicola J. Cook et al.   SCIENCE

Emergent resistance to dolutegravir among INSTI-naive patients on first-line or second-line antiretroviral therapy: a review of published cases

(2020) Muge Cevik et al.   Open Forum Infectious Diseases

HIV-1 Integrase Inhibitors that are active against Drug-Resistant Integrase Mutants

(2020) Steven J. Smith et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen

(2020) Jean van Wyk et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials

(2020) Chloe Orkin et al.   Lancet HIV

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults

(2020) Michael S. Saag et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Simulating HIV Breakthrough and Resistance Development During Variable Adherence to Antiretroviral Treatment

(2020) Andrew Mulato et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Adherence to HIV treatment regimens: systematic literature review and meta-analysis

(2019) Frederick Altice et al.   Patient Preference and Adherence

Efficacy and safety of dolutegravir–rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies

(2019) Michael Aboud et al.   Lancet HIV

Management of Virologic Failure and HIV Drug Resistance

(2019) Suzanne M. McCluskey et al.   INFECTIOUS DISEASE CLINICS OF NORTH AMERICA

Failure of Dolutegravir First-Line ART with Selection of Virus Carrying R263K and G118R

(2019) Nadine Lübke et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dolutegravir Plus Rilpivirine as a Switch Option in cART-Experienced Patients: 96-Week Data

(2018) Amedeo Ferdinando Capetti et al.   ANNALS OF PHARMACOTHERAPY

Emergence of Integrase Resistance Mutations During Initial Therapy Containing Dolutegravir

(2018) Jennifer A Fulcher et al.   CLINICAL INFECTIOUS DISEASES

Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial

(2018) Jose L Blanco et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies

(2018) Josep M Llibre et al.   LANCET

Efficacies of Cabotegravir and Bictegravir against drug-resistant HIV-1 integrase mutants

(2018) Steven J. Smith et al.   Retrovirology

Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial

(2018) Jean-Michel Molina et al.   Lancet HIV

Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial

(2018) Eric S Daar et al.   Lancet HIV

Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir

(2018) Maureen Oliveira et al.   Retrovirology

New Dual Combination of Dolutegravir-Rilpivirine for Switching to Maintenance Antiretroviral Therapy

(2018) Esteve Ribera   AIDS REVIEWS

Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA

(2018) Amesika N Nyaku et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

(2018) Pedro Cahn et al.   LANCET

Virological Failure in HIV to Triple Therapy With Dolutegravir-Based Firstline Treatment: Rare but Possible

(2018) M J Pena et al.   Open Forum Infectious Diseases

Viability of primary osteoblasts after treatment with tenofovir alafenamide: Lack of cytotoxicity at clinically relevant drug concentrations

(2017) Christian Callebaut et al.   PLoS One

Rapid In Vitro Evaluation of Antiretroviral Barrier to Resistance at Therapeutic Drug Levels

(2016) Andrew Mulato et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile

(2016) Manuel Tsiang et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Dolutegravir monotherapy as treatment de-escalation in HIV-infected adults with virological control: DoluMono cohort results

(2016) Celia Oldenbuettel et al.   ANTIVIRAL THERAPY

Effect of dolutegravir functional monotherapy on HIV-1 virological response in integrase strand transfer inhibitor resistant patients

(2016) Lisa K Naeger et al.   ANTIVIRAL THERAPY

Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation

(2015) Laura Dickinson et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Brief Report

(2015) Sharon Walmsley et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Infrequent Development of Resistance in Genotype 1–6 Hepatitis C Virus–Infected Subjects Treated With Sofosbuvir in Phase 2 and 3 Clinical Trials

(2014) Evguenia S. Svarovskaia et al.   CLINICAL INFECTIOUS DISEASES

Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir

(2014) Eric F. Donaldson et al.   HEPATOLOGY

Ritonavir-boosted darunavir combined with raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial

(2014) François Raffi et al.   LANCET

Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial

(2014) Pedro Cahn et al.   LANCET INFECTIOUS DISEASES

Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues

(2014) Courtney V. Fletcher et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Loss and Recovery of Genetic Diversity in Adapting Populations of HIV

(2014) Pleuni S. Pennings et al.   PLoS Genetics

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study

(2013) Pedro Cahn et al.   LANCET

The Use of Pill Counts as a Facilitator of Adherence with Antiretroviral Therapy in Resource Limited Settings

(2013) Loice Achieng et al.   PLoS One

Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure

(2013) Thibault Mesplède et al.   Retrovirology

HIV Latency

(2013) R. F. Siliciano et al.   Cold Spring Harbor Perspectives in Medicine

Development of Elvitegravir Resistance and Linkage of Integrase Inhibitor Mutations with Protease and Reverse Transcriptase Resistance Mutations

(2012) Mark A. Winters et al.   PLoS One

Pharmacokinetics of Lamivudine and Lamivudine-Triphosphate after Administration of 300 Milligrams and 150 Milligrams Once Daily to Healthy Volunteers: Results of the ENCORE 2 Study

(2011) Laura J. Else et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Transmission dynamics of the M184V drug resistance mutation in primary HIV infection

(2011) M. A. Wainberg et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Characterization of the R263K Mutation in HIV-1 Integrase That Confers Low-Level Resistance to the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir

(2011) P. K. Quashie et al.   JOURNAL OF VIROLOGY

In VitroAntiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor

(2010) Masanori Kobayashi et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Estimation of inhibitory quotient using a comparative equilibrium dialysis assay for prediction of viral response to hepatitis C virus inhibitors

(2010) H. Mo et al.   JOURNAL OF VIRAL HEPATITIS

Forgiveness of non-adherence to HIV-1 antiretroviral therapy

(2008) J. Shuter   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY